Grethe Nørskov Rasmussen
Corporate Officer/Principal en FLUOGUIDE A/S .
Fortuna: 2 M $ al 30/04/2024
Cargos activos de Grethe Nørskov Rasmussen
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| FLUOGUIDE A/S | Corporate Officer/Principal | 01/01/2019 | - |
Historial de carrera de Grethe Nørskov Rasmussen
Antiguos cargos conocidos de Grethe Nørskov Rasmussen.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ASCENDIS PHARMA A/S | Corporate Officer/Principal | 08/04/2010 | 01/01/2019 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | 01/01/2000 | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | 01/01/1989 | - |
Formación de Grethe Nørskov Rasmussen.
| Technical University of Denmark | Doctorate Degree |
Estadísticas
Internacional
| Dinamarca | 5 |
| Estados Unidos | 2 |
Operativa
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| ASCENDIS PHARMA A/S | Health Technology |
| NOVO NORDISK A/S | Health Technology |
| FLUOGUIDE A/S | Health Technology |
| Empresas privadas | 1 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
